Seres Therapeutics
@SeresTX
Followers
2,477
Following
235
Media
323
Statuses
696
Seres Therapeutics is developing revolutionary microbiome-based therapeutics to treat serious diseases. See our Twitter Guidelines here:
Cambridge, MA
Joined January 2015
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Cheney
• 468785 Tweets
Texas
• 229611 Tweets
Michigan
• 189797 Tweets
England
• 148330 Tweets
Mustafa Kemal
• 133881 Tweets
Ireland
• 123315 Tweets
MSNBC
• 74358 Tweets
Lookman
• 47456 Tweets
Nelly
• 38557 Tweets
Grealish
• 32893 Tweets
Arkansas
• 29646 Tweets
Kentucky
• 29036 Tweets
#كاريزما63
• 24590 Tweets
Iowa
• 24026 Tweets
Musiala
• 21052 Tweets
Ohio State
• 16289 Tweets
Penn State
• 16106 Tweets
Pedro Almodóvar
• 15876 Tweets
#BaşkomutanErdoğan
• 14579 Tweets
Sabalenka
• 14004 Tweets
#الهلاليين_يرفضون_لودي
• 13010 Tweets
León de Oro
• 11538 Tweets
Auburn
• 11521 Tweets
Riya
• 10997 Tweets
Sellers
• 10271 Tweets
We are pleased to announce positive topline results from our SER-109 Phase 3 ECOSPOR III study in recurrent C. diff infection. Read the release here:
6
20
75
BREAKING: The first orally administered
#microbiota
-based therapeutic has been approved by the U.S. FDA. Learn more:
4
17
63
We received approval for the first orally administered
#microbiota
-based therapeutic by the U.S. FDA, and we are committed to bringing this new option to patients. Learn more:
3
12
44
#Cdiff
has been classified by the
#CDC
as one of the greatest microbial threats to human health and the leading cause of hospital-acquired infections in the United States. Do you know how many cases of recurrent C. diff infections there are in the US per year?
approximately 170,000
130
approximately 320,000
327
approximately 550,000
508
12
16
40
We are excited to announce that data from our Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral
#microbiome
therapeutic for recurrent
#Cdiff
infection, was published in the New England Journal of Medicine. Learn more:
@NEJM
2
13
27
Today, we announced that the first orally administered
#microbiota
-based therapeutic approved by the FDA is now commercially available for patients in the U.S. Learn more:
2
8
26
Today, we entered into an agreement w/ partner
@NestleHealthUS
to acquire Vowst, a deal that allows us to focus on our pioneering mission of advancing revolutionary microbiome therapeutics for as many patients as possible.
104
5
25
#ICYMI
We were named one of the
@TIME
100 Most Influential Companies of 2023 in the ‘Pioneers’ category! We’re
#SeresProud
of this recognition and excited for the future of the
#microbiome
. Learn more:
#TIME100Companies
0
4
23
We are thrilled to report initial Phase 1b study results for investigational, cultivated
#microbiome
therapeutic SER-155. Read the full release for more:
1
4
20
We are excited to share that the FDA has accepted for priority review our Biologics License Application for investigational
#microbiome
therapeutic SER-109 in recurrent
#Cdiff
. Learn more:
0
7
17
We are proud to announce confirmatory results from our ECOSPOR IV open-label study of investigational
#microbiome
therapeutic SER-109 in recurrent
#Cdiff
. Read more:
1
6
10
At Seres, we have been pioneering the development of microbiome therapeutics since 2011. As a
#FlagshipFounded
company, we took bold leaps in 2023 to transform the lives of patients as we received FDA approval for the first orally administered microbiome-based therapeutic. We're
0
2
17
We’re
#SeresProud
to announce we’ve entered into a strategic collaboration with
@NestleNHSc
to jointly commercialize SER-109, our investigational oral
#microbiome
therapeutic for recurrent
#Cdiff
, in the U.S. & Canada. Read more:
1
5
16
Seres is excited to present new preliminary data on investigational
#microbiome
therapeutic SER-155 from the first cohort (open-label) of our Phase 1b study in hematopoietic stem cell transplant patients at
#ASCO24
in Chicago.
Join us at the poster session on June 3rd at 9am
4
4
16
We’re
#SeresProud
to be one of the
@TIME
100 Most Influential Companies of 2023. Thank you to our colleagues & collaborators for being part of our journey to transform the lives of patients with revolutionary
#microbiome
therapeutics.
#TIME100Companies
0
3
16
Seres is featured in this Science article exploring how the gut microbiome influences cancer treatment – with a spotlight on our work in immuno-oncology in collaboration with our partners
@parkerici
and
@MDAndersonNews
. Check it out here:
0
7
16
We are excited to share we’ve completed the submission process for our Biologics License Application to the FDA for investigational
#microbiome
therapeutic SER-109 in recurrent
#Cdiff
. Learn more:
0
6
15
Last week we shared new mechanistic data on SER-287, our investigational
#microbiome
therapy for
#UlcerativeColitis
. SER-287 produced remission-associated metabolites, reduced inflammation and protected epithelial barrier function in vitro.
#CCCongress21
1
4
13
Halfway through Day 1 of
#DDW2021
and feeling inspired by Dr. Mark Wilcox’s plenary session, “Are We There Yet? Role of Defined Microbial Consortia in Treatment of GI Disease.” Dr. Wilcox shared an in-depth look at
#microbiome
therapeutics and the Seres platform.
0
6
14
Seres has completed enrollment for Cohort 2 of the Phase 1b clinical trial of SER-155 in Allo
#HSCT
patients, bringing us closer to potentially revolutionizing the approach to enteric-derived and bloodstream infections post-transplantation.
1
3
14
We are
#SeresProud
to be presenting and sponsoring the 27th Annual
@BostonBacteria
Meeting. Learn more about the meeting:
#BBM2021
0
2
13
We’re deeply saddened by the passing of Nancy Caralla, founder of
@cdiffFoundation
& an influential patient advocate within the C. diff community. We were honored to work with Nancy & will miss her kind spirit. Seres is dedicated to continuing her legacy.
2
3
13
We’re attending
@DDWMeeting
where we’ll highlight clinical trial data for the first orally administered
#microbiota
-based therapeutic. Learn more:
#DDW2023
0
3
12
We’re
#SeresProud
and grateful to be part of working toward advancements in the
#microbiome
field. We’re thankful for our team, healthcare providers, patients and their families, and everyone working to make a difference.
#HappyThanksgiving
1
2
12
Alongside our collaborator, Nestle Health Science, we are executing the launch our oral microbiome therapy in the United States. In today’s Q2 2023 earnings report, we were pleased to announce highly encouraging initial launch results.
3
2
12
For
#MicrobiomeMonday
meet the Firmicutes, the beneficial bacteria that are abundant in the healthy human gut. Many Firmicutes produce spores that allow them to survive stomach acid and allow us to package them into convenient oral capsules.
0
1
11
Seres Chief Technology Officer Dr. John Aunins received the D.I.C. Wang Award for Excellence in Biochemical Engineering this week. Congratulations to Dr. Aunins for nearly three decades of meaningful contributions to biotech. Read more award info here:
1
0
11
November is
#cdiff
awareness month & we're wearing our ribbons to show support!
#CdiffInfectionAwareness
1
2
10
Seres $MCRB is excited to announce a three-year research collaboration with
@AstraZeneca
to advance the development of new potential microbiome-based therapies for cancer. Read more details in today’s release:
0
7
11
Join Dr. Louis Korman today at 11:00AM ET at the research forum to learn about clinical data for the first orally administered
#microbiota
-based therapeutic. Learn more:
#DDW2023
0
2
10
We’re at
#ASMicrobe
2023, presenting during the
@ASMicrobiology
’s Emerging Science Rapid Fire session! Learn more:
0
1
11
The bacteria in our microbiomes are essential to human health. Learn about some of the biological processes they aid in:
0
9
11
Antimicrobial resistance (
#AMR
) is one of our greatest public health threats, and the situation is worsening. In
@statnews
we explain why innovative
#microbiome
therapeutic options may be important for combating antibiotic resistance:
1
2
11
At Seres we are evaluating whether our
#microbiome
therapeutics can induce remission in ulcerative colitis. In an early study, 40% of UC patients achieved remission after 8 weeks. Learn more and see if you qualify:
0
6
10
We’re proud to share positive SER-287 Phase 1b
#UlcerativeColitis
results in
@AGA_Gastro
. Our investigational
#microbiome
therapeutic made this month’s cover! Read more:
0
4
11
In honor of
#CdiffAwarenessMonth
, Christian Lillis, co-founder of the
@PeggyFund
, shares how
#Cdiff
impacted his family and why it important to spread awareness and advocate for patients with this disease. Read more:
0
9
11
We're attending
#ASCO23
! We're eager to learn from and share ideas with some of the greatest minds in the industry as we continue focusing on
#microbiome
therapeutics for Infection Protection. Join us:
@ASCO
0
3
10
We’re on a mission to revolutionize
#microbiome
therapeutics.
This summer, all of our teams came together to collaborate on achieving our goals to better serve patients and celebrate our progress to date. We couldn’t be more
#SeresProud
of our team!
0
0
11
Today our CEO Roger Pomerantz provided a company update at
#JPM18
, including a discussion of new
#microbiome
results from our Phase 1b study of SER-287 in
#ulcerativecolitis
. View the webcast here:
0
6
9
The first patient has been enrolled in our Phase 1b study of SER-155, an investigational
#microbiome
therapeutic designed to reduce the risk of antibiotic-resistant bacterial infections &
#GvHD
in adults receiving allogeneic
#HSCT
. Learn more:
0
2
10
This morning we reported
#microbiome
analyses for our investigational SER-287 microbiome candidate in
#ulcerativecolitis
. Details here:
0
5
8
Last week, we announced the publication of Phase 3 ECOSPOR III study data in the New England Journal of Medicine highlighting SER-109, an investigational oral
#microbiome
therapeutic for recurrent
#Cdiff
infection. Learn more:
#ICYMI
1
5
10
Our team had a great time at Friday’s
#BioBall
event, sponsored by Special Olympics Massachusetts. Not only was it fun to get together, but we helped raise money to support our local
#SpecialOlympics
athletes!
Learn more about the cause:
3
0
10
The
#microbiome
could play a role in improving cancer treatment outcomes by modifying immune responses to chemo- and
#immunotherapy
. See Seres’ and
@AstraZeneca
’s recently published IOTECH paper for the latest insights into leveraging these benefits:
0
6
10
Today we’re in NYC discussing the
#microbiome
as a new therapeutic target, with a focus on our pipeline and the opportunity for microbiome therapeutics to impact immune biology. Learn more:
0
4
10
Closing out C. diff awareness month with a team photo! A big thank you to
@CDiffFoundation
for their hard work raising awareness.
#cdiff
#cdiffawareness
#microbiome
1
3
9
This morning we announced that the
@US_FDA
has granted Orphan Drug Designation to SER-287 for the treatment of
#ulcerativecolitis
in pediatric patients. Details here:
0
9
9
For our first
#MicrobiomeMilestonesMonday
, we’re going back to the beginning: when the human
#microbiome
was first discovered. In the 1670s, Antonie van Leeuwenhoek first described bacteria, after observing them with a handcrafted microscope. Learn more:
0
2
10
Approximately 170,000 patients in the U.S. suffer from recurrent C. difficile infection annually. SER-109 could potentially provide a much-needed effective oral treatment option for these individuals. Learn more:
0
6
10
We are pleased to share that we have achieved target enrollment in our Phase 2b ECO-RESET clinical study of SER-287, our investigational
#microbiome
therapeutic for patients with mild-to-moderate ulcerative colitis (UC). More information in our release:
0
1
10
We’re
#SeresProud
to celebrate the grand opening of our new CLIA lab with a ribbon-cutting ceremony in Lower Gwynedd, Pa.
This new donor screening facility will allow us to continue our mission to transform patients’ lives by revolutionizing
#microbiome
therapeutics.
15
1
9
Today and tomorrow at
@IDWeek2020
Seres will be hosting a Learning Lounge presentation on
#cdiff
with Dr. Mark Wilcox. Visit to learn more about our unique
#microbiome
therapeutic approach to recurrent
#cdiff
.
#IDWeek2020
0
2
8
We have a deep understanding of the critical role the
#microbiome
plays in our health – and we’re leveraging that understanding to develop novel therapeutics with the potential to create a new treatment paradigm. Learn more:
0
1
8
Today is
#WorldMicrobiomeDay
!
#DYK
microbes are crucial to our health? That’s why we’re dedicated to leading the
#microbiome
revolution. Learn more:
#Microbiomes4Life
@WMicrobiomeDay
0
4
9
Today is
#WorldIBDDay
. Join us as we raise awareness for those living with chronic digestive diseases. Want to learn more about IBD? Check out our website:
#IBDvisible
#ECORESET
1
4
9
#SeresTX
was at the Crohn's & Colitis Congress recently to present data on SER-287, our investigational therapy for
#ulcerativecolitis
– which is currently being investigated in ECO-RESET, a Phase 2b study. See here to learn more:
0
4
8
We are excited to announce the completion of enrollment of our ECOSPOR III trial of SER-109, a live
#microbiome
therapeutic being investigated for recurrent
#Cdiff
infection. See our release for details and an update on our other clinical programs:
0
3
9
Our team has deep scientific understanding of the
#microbiome
, and we’re continuously building upon our knowledge. Check out our recent publications sharing new insights into the microbiome’s potential as a therapeutic modality here:
#WorldMicrobiomeDay
0
1
9
Our Quality Control Center of Excellence is officially open in Waltham! This project started as a vision 3 years ago & we are
#SeresProud
to have made it a reality. This center helps us continue our mission of working to transform patients’ lives with
#microbiome
therapeutics.
0
0
9
Attention
#FierceNPP
attendees! Join our Chief Commercial & Strategy Officer Terri Young today at 9:00AM ET to hear insights and best practices drawn from her experience.
#SeresProud
@LifeSciEvents
2
1
9
Delighted to host at
#SeresTx
@SamGymiah
, a member of the British Parliament and Minister for Universities, Science, Research & Innovation. Proud to be working with
@CARB_X
to find new solutions to
#antibioticresistance
.
Anti-microbial resistance is one of the greatest threats to global health & food security according to
@WHO
, and why as part of my visit to Boston, I visited Seres Therapeutics who are working in a £500m UK-US partnership with
@wellcometrust
&
@gatesfoundation
to find a solution
6
31
62
0
2
9
Matt Henn (
@microbiologic
) here, and I’m taking over
@SeresTX
today as we dive into Day 1 of
#DDW2021
. Be sure to follow along!
0
1
9
We are excited to welcome Terri Young, PhD, RPh to the Seres team as Chief Commercial and Strategy Officer! Dr. Young joins ahead of the readout from the pivotal Phase 3 trial of our lead
#microbiome
therapeutic candidate, SER-109.
0
2
9
We’re conducting an open-label study for SER-109, our
#microbiome
therapeutic for
#cdiff
recurrence that showed clinically meaningful efficacy in our phase 3 clinical trial. Now enrolling nationwide — learn if you qualify and find a site near you:
0
5
8
We’re proud to announce our collaboration with
@MDAndersonNews
&
@parkerici
to support the investigation of
#microbiome
therapeutics for
#ImmunoOncology
. Read more:
1
4
9
We are
#SeresProud
to share that we’ve initiated an expanded access program for our investigational
#microbiome
therapeutic SER-109 for eligible patients with recurrent
#Cdiff
infection. This will allow compassionate use for patients in need. Learn more:
0
3
8
In 2020 we advanced our research, welcomed new team members and announced positive topline clinical results for SER-109. A heartfelt thank you to our team, our collaborators and partners, our CROs and the subjects participating our studies. We're ready and excited for 2021!
0
0
9
We’re enrolling patients in the US & Canada in an open-label study for SER-109, our investigational
#microbiome
therapeutic to prevent
#cdiff
recurrence:
In a Phase 3 clinical trial, SER-109 significantly reduced recurrence compared to antibiotics alone.
0
2
9
Seres is proud to support Special Olympics Massachusetts through our annual Bio-Ball fundraising. This year, we raised over $17,700!! Thanks to Maggie Bryant for coordinating and for all of those who continue to make Seres a great place to work.
#marchmadness
#bioball
1
2
9
#NationalWalkingDay
: Walking is a great way to maintain your health. It strengthens bones and muscles, improves heart health, boosts energy, aids digestion and a lot more. At Seres, we’re passionate about health and will be lacing up our sneakers today.
#GetWalking
0
1
9
If you are attending
@DDWMeeting
, tune into our
#DDW2023
presentation today at 1:30PM ET to hear from Dr. Darrell Pardi, head of
#GI
at the
@MayoClinic
.
2
3
8
We’re proud to announce the dosing of the first patient in our Ph 1b trial of SER-301, a multi-strain live
#microbiome
therapeutic designed to treat
#UlcerativeColitis
. We continue to incorporate learnings from our clinical studies and R&D. More info:
1
2
9
Our Greater Boston area teams are
#SeresProud
to volunteer with
@CircleofHopeBOS
to create and donate 500 dignity bags of hygiene essentials & 600 COVID kits to help underserved communities stay healthy and safe. Thank you
@LS_Cares
for helping organize this event!
0
1
7
As part of
#Cdiff
Awareness Month, it’s important to highlight how C. diff impacts the lives of survivors and their families. Thank you to Renata for sharing her story & to the
@cdiffFoundation
for its longstanding efforts to spread awareness about CDI.
0
3
7
#ICYMI
Last week, Seres joined a podcast with the
@cdiffFoundation
. Members of our team talked with CDF's executive director and founding president, Nancy Caralla, about the promising results of our company's SER-109 study. Click here to listen:
0
4
8
Congrats to this year’s
#NobelPrize
winners and
#immunooncology
pioneers, Dr. Allison & Dr. Honju. We are proud to be partnering with
@MDAndersonNews
and
@parkerici
to advance SER-401 to improve immunotherapy patient outcomes.
0
3
8
We are excited to share data from our Phase 3 ECOSPOR III study of investigational oral microbiome therapeutic SER-109 at
@DDWMeeting
later this month. Learn more:
#DDW2022
0
4
7
We’re
#SeresProud
of our Spring 2023 Co-Op class!
We’re excited to collaborate with this latest cohort of highly motivated students who want to transform the lives of patients with revolutionary
#microbiome
therapeutics.
0
0
8
We’re at the 8th Annual
@MicrobiomeDaily
Summit! Our Seres team is there to discuss insights about our pipeline and the future of the
#microbiome
. Learn more:
#MicrobiomeMovement
0
1
7
We are excited to welcome Dr. Lisa von Moltke as Chief Medical Officer. Lisa brings extensive experience directing multiple successful clinical programs. More in today’s release:
0
1
7
Happy holidays from all of us at Seres! We wish everyone a joyous holiday season. We hope the new year brings you all peace, good health and good cheer!
0
0
7
We’ve announced late-breaking data from our Phase 3 ECOSPOR III study for investigational
#microbiome
therapeutic SER-109 in recurrent
#Cdiff
infection in patients with risk factors for recurrence, including acid-reducing medications. Learn more:
#ACG2021
2
3
8
We’re conducting an open-label research study for SER-109, our investigational
#microbiome
therapeutic for recurrent
#cdiff
in the US and Canada. Find a site near you:
0
3
7
What a year it has been with so many exciting advancements in the
#microbiome
industry, and many more to come in the new year. We are
#SeresProud
of our 2021 accomplishments and can’t wait to continue our progress in 2022!
0
1
8
We are
#SeresProud
of the first group of “Seres Scholars” graduates! We’re excited about the future of this program, developed in partnership with
@CRLSTweets
, promoting equity in education with career mentorship and other opportunities for students.
0
2
8
In a Phase 1 study, 40% of UC subjects who received our investigational
#microbiome
drug SER-287 achieved remission of
#UlcerativeColitis
after 8 weeks compared to 0% in placebo. Check out our current clinical trial for SER-287:
0
2
7
November is
#CdiffInfectionAwareness
Month, an opportunity to raise awareness about
#cdiff
infection and the need for better prevention and treatment options. Learn more about our current clinical trial in recurrent C. diff:
0
3
7
#ICYMI
, we presented at
#DDW2023
! Presentations are available for 90 days on the
@DDWmeeting
conference website here:
0
3
6
We are excited to present at
#ASCO23
! Join Bina Tejura, MD, Senior Medical Director, during the poster session starting at 9:00AM ET today to learn about our currently enrolling Phase 1b study of investigational
#microbiome
therapeutic SER-155. More:
@ASCO
0
3
7
Today is
#WomensEqualityDay
and we’re proud to empower our colleagues. Hear from Seres VP of Marketing Amy Muse on what this day means to her.
0
0
7
Today, our Chief Scientific Officer & EVP
@microbiologic
joins the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria to discuss the potential for
#microbiome
live biotherapeutics (2:30pm ET). Learn more:
#SeresProud
#PACCARB
@HHSGov
0
4
7
Pleased to announce we’ve received a
@CARB_X
grant to develop microbiome therapeutics to combat
#AntibioticResistance
0
6
7
